PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD

44.00

-0.57 (-1.28%)

At close: 4:02PM EDT

Stock chart is not supported by your current browser

Previous Close	44.57
Open	44.34
Bid	0.00 x 3100
Ask	0.00 x 1100
Day's Range	43.71 - 44.50
52 Week Range	33.20 - 45.81
Volume	21,345,724
Avg. Volume	20,659,512

Market Cap	257.933B
Beta (3Y Monthly)	0.84
PE Ratio (TTM)	11.75
EPS (TTM)	3.74
Earnings Date	Oct 30, 2018
Forward Dividend & Yield	1.36 (3.05%)
Ex-Dividend Date	2018-11-08
1y Target Est	42.94

Trade prices are not sourced from all markets

All

News

Press Releases

Reuters55 minutes ago
Australian watchdog's appeal against Pfizer ruling dismissed by court
The Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies. The drug stores were said to have bought large quantities of the drug and agreed to limit re-supply of competing generic atorvastatin products.
Reuters56 minutes ago
Australian watchdog's appeal against Pfizer ruling dismissed by court
Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor. The Australian Competition and Consumer Commission (ACCC) sought leave to appeal against a judgment by a Federal Court in May, when Pfizer was alleged to have abused its market power by offering big discounts and rebates on Lipitor to pharmacies.
Market Realist8 hours ago
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Market Realist10 hours ago
What Are Pfizer’s Revenue Drivers?
Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.
Market Realist11 hours ago
Novartis Missed Revenue Estimates in Q3 2018
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
Market Realist11 hours ago
Pfizer’s Market Cap and Shareholding Pattern
As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segment—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.
Market Realist11 hours ago
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
CNBC13 hours ago
Dow stocks Pfizer and UnitedHealth could be safety plays amid market volatility
In a wild week for the Dow , one corner of the index has proven immune to the worst of the volatility: health care. Dow stocks Pfizer PFE , UnitedHealth UNH and Merck MRK remain within reach of 52-week highs, while the Dow hangs 5 percent from its own.
TheStreet.com14 hours ago
Pfizer Confirms to Cut Workforce by 2%
is looking to cut its total workforce of 90,000 "by a couple percentage points," TheStreet confirmed on Thursday, Oct. 18. The staff cuts "will affect some managerial roles and responsibilities," said company spokeswoman, Sally Beatty, in an email to TheStreet. Earlier, CNBC reported on an internal memo to employees asking workers to retire early to offset the number of people who would need to be laid off.
Markit16 hours ago
See what the IHS Markit Score report has to say about Pfizer Inc.
Pfizer Inc NYSE:PFE
Reuters17 hours ago
Merck, Pfizer combo treatment meets main goals of kidney cancer trial
The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent. Keytruda is a blockbuster medicine that targets a blockade of proteins known as PD-1 and is approved for a range of other cancers, including lung cancer.
Reuters17 hours ago
Merck, Pfizer combo treatment meets main goals of kidney cancer trial
Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer. The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent.
Motley Fool18 hours ago
Is Sangamo Therapeutics Inc. a Buy?
Can this beaten-down gene-editing and gene therapy biotech bounce back?
InvestorPlaceyesterday
Pfizer Layoffs: Company to Offer Early Retirement Deals Ahead of Cuts
A new round of Pfizer layoffs (NYSE:PFE) has been announced by the pharmaceutical giant as the company is seeking to offer early retirement deals to some of its workers before gearing itself to carry out jobs cuts this year. The company made an internal announcement to its employees regarding the job cuts, although it is unclear how many of its 90,000 global workers it plans on laying off. “As we prepare for growth we are creating a simpler more efficient structure which will affect some managerial roles and responsibilities.
Motley Foolyesterday
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
American City Business Journalsyesterday
Pfizer outlines early retirement program ahead of layoffs
People who are 55 and have at least 10 years of service at the New York company may be eligible for early retirement.
Reutersyesterday
Pfizer to cut around 2 percent of jobs through early next year
U.S. drugmaker Pfizer Inc (PFE.N) plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities. Pfizer has around 90,000 employees worldwide. The move follows the announcement earlier this month that Chief Operating Officer Albert Bourla would succeed Ian Read as chief executive in January.
Reutersyesterday
Pfizer to cut around 2 percent of jobs through early next year
U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities. Pfizer has around 90,000 employees worldwide. The move follows the announcement earlier this month that Chief Operating Officer Albert Bourla would succeed Ian Read as chief executive in January.
CNBC2 days ago
Drug giant Pfizer offers early retirement ahead of layoffs in memo to employees
Pfizer is offering early retirement to eligible U.S. employees, ahead of layoffs next year. The pharmaceutical giant currently employs more than 90,000, according to data compiled by Factset. Pharmaceutical giant Pfizer PFE is offering early retirement to U.S. workers ahead of layoffs early next year, it announced internally to employees.
Zacks2 days ago
Top Research Reports for Pfizer, Caterpillar & Charter Communications
Top Research Reports for Pfizer, Caterpillar & Charter Communications
Zacks2 days ago
Pfizer (PFE) Gains But Lags Market: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $43.92, marking a +1.86% move from the previous day.
Yahoo Finance2 days ago
Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.
Market Realist2 days ago
What Nektar Therapeutics’ Valuation Trend Indicates
In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.
CNBC Videos11 hours ago
Will Pfizer hit $50? Is Cleveland-Cliffs a safe bet ahead...
The "Halftime Report" traders take viewer questions on Pfizer, Mosaic and Cleveland-Cliffs.
CNBC Videos2 days ago
Battle brewing over TV drug ads
Will drug ads dry up under the new Trump regulations? With CNBC's Meg Tirrell and Melissa Lee, and the Fast Money traders, Tim Seymour, Karen Finerman, Steve Grasso and Guy Adami.